Associated Papers
Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y et al.
Scientific Reports, 2024
38238401 (PubMed )
Supplement: 41598_2024_52006_MOESM1_ESM.xlsx › Supplementary_Table_all_list
Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China.
Wang Y et al.
Pharmacology, 2021
Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations.
Heng W et al.
Lung Cancer (amsterdam, Netherlands), 2019
Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients.
Deng Q et al.
Heliyon, 2018
30603682 (PubMed )
Supplement: mmc2.xlsx › Raw_reads_info
Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
Martín Martorell P et al.
Clinical Lung Cancer, 2017
MBASED: allele-specific expression detection in cancer tissues and cell lines.
Mayba O et al.
Genome Biology, 2014
Select a paper to view details